Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 USD | -4.84% | -7.09% | -37.23% |
May. 15 | HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating | MT |
May. 14 | IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 1.5M | Capitalization | 77.74M |
---|---|---|---|---|---|
Net income 2024 * | -84M | Net income 2025 * | -120M | EV / Sales 2024 * | - |
Net cash position 2024 * | 37.38M | Net cash position 2025 * | 266M | EV / Sales 2025 * | -126 x |
P/E ratio 2024 * |
-0.84
x | P/E ratio 2025 * |
-0.91
x | Employees | 68 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.77% |
Latest transcript on IO Biotech, Inc.
1 day | -4.84% | ||
1 week | -7.09% | ||
1 month | -19.18% | ||
3 months | -26.25% | ||
6 months | +0.85% | ||
Current year | -37.23% |
Managers | Title | Age | Since |
---|---|---|---|
Mai-Britt Zocca
FOU | Founder | 56 | 14-11-30 |
Amy Sullivan
DFI | Director of Finance/CFO | 54 | 22-10-14 |
Eric Faulkner
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Smith
BRD | Director/Board Member | 64 | 22-02-28 |
K. Hirth
CHM | Chairman | 72 | 16-08-31 |
Kathleen Glaub
BRD | Director/Board Member | 70 | 18-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.18 | -4.84% | 107,793 |
24-05-30 | 1.24 | +0.81% | 95,997 |
24-05-29 | 1.23 | -4.65% | 101,675 |
24-05-28 | 1.29 | +1.57% | 147,610 |
24-05-24 | 1.27 | -3.79% | 68,394 |
Delayed Quote Nasdaq, May 31, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.23% | 77.74M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- IOBT Stock